Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg-positive chronic hepatitis B.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
03
10
2022
received:
05
09
2022
accepted:
28
10
2022
pubmed:
26
11
2022
medline:
16
2
2023
entrez:
25
11
2022
Statut:
ppublish
Résumé
We investigated associations between hepatitis B virus (HBV) genome-length haplotype number (HN) at baseline in subjects with HBeAg-positive chronic hepatitis B (CHB), and the likelihood of achieving functional cure during direct-acting antiviral therapy METHOD: We analysed 86 HBeAg-positive baseline samples from patients with HBV genotypes A and D who were enrolled in a Phase II trial of tenofovir disoproxil fumarate (TDF) to determine if HN was a biomarker of HBsAg loss during therapy. Findings were validated using baseline samples from 181 patients with HBV genotypes A and D from an independent clinical trial utilising TDF or tenofovir alafenamide therapy in HBeAg-positive CHB. In the HBeAg-positive test cohort, patients with genotypes A or D and ≤2 haplotypes had a minimum of 21-fold higher likelihood of achieving HBsAg loss on TDF. Baseline HN (p < 0.0001) was a stronger predictor of HBsAg loss on therapy than HBsAg titre (p = 0.03), HBeAg titre (p = 0.0002), or the presence of HBV basal core promoter (A1762T, p = 0.0379 and G1764A, p = 0.0176) or G1896A precore mutations (p = 0.0218). This finding was validated in the independent validation cohort. HN was statistically higher in patients with HBV genotypes B or C infection compared to genotypes A and D. Baseline HN ≤2 predicts which patients with HBV genotypes A or D will more likely progress to functional cure on current direct-acting antiviral therapy, with greater accuracy than current biomarkers including baseline HBsAg and HBeAg titre.
Sections du résumé
BACKGROUNDS AND AIMS
We investigated associations between hepatitis B virus (HBV) genome-length haplotype number (HN) at baseline in subjects with HBeAg-positive chronic hepatitis B (CHB), and the likelihood of achieving functional cure during direct-acting antiviral therapy METHOD: We analysed 86 HBeAg-positive baseline samples from patients with HBV genotypes A and D who were enrolled in a Phase II trial of tenofovir disoproxil fumarate (TDF) to determine if HN was a biomarker of HBsAg loss during therapy. Findings were validated using baseline samples from 181 patients with HBV genotypes A and D from an independent clinical trial utilising TDF or tenofovir alafenamide therapy in HBeAg-positive CHB.
RESULTS
In the HBeAg-positive test cohort, patients with genotypes A or D and ≤2 haplotypes had a minimum of 21-fold higher likelihood of achieving HBsAg loss on TDF. Baseline HN (p < 0.0001) was a stronger predictor of HBsAg loss on therapy than HBsAg titre (p = 0.03), HBeAg titre (p = 0.0002), or the presence of HBV basal core promoter (A1762T, p = 0.0379 and G1764A, p = 0.0176) or G1896A precore mutations (p = 0.0218). This finding was validated in the independent validation cohort. HN was statistically higher in patients with HBV genotypes B or C infection compared to genotypes A and D.
CONCLUSION
Baseline HN ≤2 predicts which patients with HBV genotypes A or D will more likely progress to functional cure on current direct-acting antiviral therapy, with greater accuracy than current biomarkers including baseline HBsAg and HBeAg titre.
Substances chimiques
Hepatitis B e Antigens
0
Hepatitis B Surface Antigens
0
Antiviral Agents
0
Tenofovir
99YXE507IL
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
509-523Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2021: accountability for the global health sector strategies, 2016-2021: actions for impact [Internet]. 2021. Available from: https://www.who.int/publications/i/item/9789240027077. Accessed 1 Jun 2022.
World Health Organization. Hepatitis B. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed 1 Jun 2022.
Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545-58. https://doi.org/10.1016/S2468-1253(19)30119-0
Yip TC-F, Lok AS-F. How do we determine whether a functional cure for HBV infection has been achieved? Clin Gastroenterol Hepatol. 2020;18(3):548-50. https://doi.org/10.1016/j.cgh.2019.08.033
Alawad AS, Auh S, Suarez D, Ghany MG. Durability of spontaneous and treatment-related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol. 2020;18(3):700-709.e3. https://doi.org/10.1016/j.cgh.2019.07.018
Yeo YH, Ho HJ, Yang H-I, Tseng TC, Hosaka T, Trinh HN, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635-646.e9. https://doi.org/10.1053/j.gastro.2018.10.027
Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017;66(11):2013-23. https://doi.org/10.1136/gutjnl-2015-309300
Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57(3-4):141-50. https://doi.org/10.1159/000360947
Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16(8):1169-86. https://doi.org/10.3851/IMP1982
Brown JL, Carman WF, Thomas HC. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology. 1992;15(1):144-8. https://doi.org/10.1002/hep.1840150124
Domingo E, Perales C. Viral quasispecies. PLOS Genet. 2019;15(10):e1008271. https://doi.org/10.1371/journal.pgen.1008271
Liu S-L, Rodrigo AG, Shankarappa R, Learn GH, Hsu L, Davidov O, et al. HIV quasispecies and resampling. Science. 1996;273(5274):415-6. https://doi.org/10.1126/science.273.5274.415
Pandit A, de Boer RJ. Reliable reconstruction of HIV-1 whole genome haplotypes reveals clonal interference and genetic hitchhiking among immune escape variants. Retrovirology. 2014;11(1):56. https://doi.org/10.1186/1742-4690-11-56
Tsukiyama-Kohara K, Kohara M. Hepatitis C virus: viral quasispecies and genotypes. Int J Mol Sci. 2017;19(1):23. https://doi.org/10.3390/ijms19010023
Park C-W, Cho M-C, Hwang K, Ko S-Y, Oh H-B, Lee HC. Comparison of quasispecies diversity of HCV between chronic hepatitis C and hepatocellular carcinoma by ultradeep pyrosequencing. Biomed Res Int. 2014;2014:1-11. https://doi.org/10.1155/2014/853076
Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky J-M. Hepatitis C virus auasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. J Virol. 2004;78(9):4617-27. https://doi.org/10.1128/JVI.78.9.4617-4627.2004
Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Suri V, et al. Analysis of hepatitis B virus haplotype diversity detects striking sequence conservation across genotypes and chronic disease phase. Hepatology. 2021;73(5):1652-70. https://doi.org/10.1002/hep.31516
Yang Z-T, Huang S-Y, Chen L, Liu F, Cai XH, Guo YF, et al. Characterization of full-length genomes of hepatitis B virus quasispecies in sera of patients at different phases of infection. J Clin Microbiol. 2015;53(7):2203-14. https://doi.org/10.1128/JCM.00068-15
Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199(9):1275-85. https://doi.org/10.1086/597808
Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis. 2013;34(4):787-98. https://doi.org/10.1093/carcin/bgs406
Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky J-M. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology. 2013;58(3):890-901. https://doi.org/10.1002/hep.26383
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. https://doi.org/10.1016/j.jhep.2017.03.021
Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442-55. https://doi.org/10.1056/NEJMoa0802878
Chan HLY, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185-95. https://doi.org/10.1016/S2468-1253(16)30024-3
Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196-206. https://doi.org/10.1016/S2468-1253(16)30107-8
Knyazev S, Tsyvina V, Shankar A, Melnyk A, Artyomenko A, Malygina T, et al. Accurate assembly of minority viral haplotypes from next-generation sequencing through efficient noise reduction. Nucleic Acids Res. 2021;49(17):e102. https://doi.org/10.1093/nar/gkab576
Thiele C, Hirschfeld G. cutpointr: improved estimation and validation of optimal cutpoints in R. J Stat Softw. 2021;98(11):1-27. https://doi.org/10.18637/jss.v098.i11
Yuen L, Revill PA, Rosenberg G, Wagner J, Littlejohn M, Bayliss J, et al. HBV variants are common in the ‘immune-tolerant’ phase of chronic hepatitis B. J Viral Hepat. 2020;27(10):1061-70. https://doi.org/10.1111/jvh.13318
Aragri M, Alteri C, Battisti A, di Carlo D, Minichini C, Sagnelli C, et al. Multiple hepatitis B virus (HBV) quasispecies and immune-escape mutations are present in HBV surface antigen and reverse transcriptase of patients with acute hepatitis B. J Infect Dis. 2016;213(12):1897-905. https://doi.org/10.1093/infdis/jiw049
Hatazawa Y, Yano Y, Okada R, Tanahashi T, Hayashi H, Hirano H, et al. Quasispecies variant of pre-S/S gene in HBV-related hepatocellular carcinoma with HBs antigen positive and occult infection. Infect Agent Cancer. 2018;13(1):7. https://doi.org/10.1186/s13027-018-0179-4
Yamani LN, Yano Y, Utsumi T, Juniastuti, Wandono H, Widjanarko D, et al. Ultradeep sequencing for detection of quasispecies variants in the major hydrophilic region of hepatitis B virus in Indonesian patients. J Clin Microbiol. 2015;53(10):3165-75. https://doi.org/10.1128/JCM.00602-15
De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1-7. https://doi.org/10.1016/j.bcp.2016.04.015
Cornberg M, Lok AS-F, Terrault NA, Zoulim F, Berg T, Brunetto MR, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV treatment endpoints conference. J Hepatol. 2020;72(3):539-57. https://doi.org/10.1016/j.jhep.2019.11.003
Yip TC-F, Wong VW-S, Tse Y-K, Liang LY, Hui VW-K, Zhang X, et al. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. Aliment Pharmacol Ther. 2020;53(2):321-31.
Chen Y, Sheen I-S, Chu C, Liaw Y. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123(4):1084-9. https://doi.org/10.1053/gast.2002.36026
Pillay S, Giandhari J, Tegally H, Wilkinson E, Chimukangara B, Lessells R, et al. Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic. Genes (Basel). 2020;11(8):949. https://doi.org/10.3390/genes11080949